CYP3A5 Antibody (F18 P3 B6): sc-53616

CYP3A5 Antibody (F18 P3 B6) is a mouse monoclonal IgG1 kappa light chain antibody that detects CYP3A5 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). Anti-CYP3A5 antibody (F18 P3 B6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CYP3A5 plays a crucial role in drug metabolism, as this enzyme is responsible for the oxidative metabolism of numerous therapeutic agents, impacting their efficacy and safety. CYP3A5 is predominantly located in the liver, gastrointestinal tract, and kidney, which are critical sites for drug processing and elimination. Expression of CYP3A5 can vary significantly among individuals due to genetic polymorphisms, leading to differences in drug response and potential adverse effects. Understanding CYP3A5 function and localization is essential for personalized medicine, as this knowledge helps predict how different patients will metabolize medications, thereby guiding dosage and treatment strategies. The CYP3A gene cluster, which includes CYP3A4, CYP3A7, and CYP3A43, is located on chromosome 7q22.1 and is vital for the metabolism of over 50% of all clinical drugs, making CYP3A5 a significant target for research and therapeutic applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP3A5 Antibody (F18 P3 B6) References:

1. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.  |  Paulussen, A., et al. 2000. Pharmacogenetics. 10: 415-24. PMID: 10898111
2. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice.  |  Stedman, C., et al. 2004. J Biol Chem. 279: 11336-43. PMID: 14681232
3. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.  |  Williams, PA., et al. 2004. Science. 305: 683-6. PMID: 15256616
4. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.  |  Fukami, M., et al. 2005. J Clin Endocrinol Metab. 90: 414-26. PMID: 15483095
5. Androgen-regulated transcripts in the neonatal mouse testis as determined through microarray analysis.  |  Zhou, Q., et al. 2005. Biol Reprod. 72: 1010-9. PMID: 15601916
6. Association of habitual smoking and drinking with single nucleotide polymorphism (SNP) in 40 candidate genes: data from random population-based Japanese samples.  |  Liu, Y., et al. 2005. J Hum Genet. 50: 62-68. PMID: 15654505
7. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.  |  Kumarakulasingham, M., et al. 2005. Clin Cancer Res. 11: 3758-65. PMID: 15897573
8. CYP3A5 polymorphism, amlodipine and hypertension.  |  Zhang, YP., et al. 2014. J Hum Hypertens. 28: 145-9. PMID: 23863802
9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.  |  Birdwell, KA., et al. 2015. Clin Pharmacol Ther. 98: 19-24. PMID: 25801146
10. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs.  |  Ragia, G., et al. 2016. Curr Drug Metab. 17: 227-36. PMID: 26651976
11. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.  |  Chen, L. and Prasad, GVR. 2018. Pharmgenomics Pers Med. 11: 23-33. PMID: 29563827
12. CYP3A5 unexpectedly regulates glucose metabolism through the AKT-TXNIP-GLUT1 axis in pancreatic cancer.  |  Shao, M., et al. 2024. Genes Dis. 11: 101079. PMID: 38560501

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CYP3A5 Antibody (F18 P3 B6) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CYP3A5 Antibody (F18 P3 B6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CYP3A5 Antibody (F18 P3 B6) Specifications

Alternate Product Name: Cytochrome P450 3A5 (CYP3A5)

Product Clone Name: F18 P3 B6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CYP3A5

Epitope Species: human

Product Reactivity/Detection: Cytochrome P4503A5

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CYP3A5 Antibody (F18 P3 B6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred CYP3A antibody is CYP3A Antibody (B-3): sc-365415.